APTT, ELT and fibrinogen were determined.

同时测定APTT 、 ELT和血浆纤维蛋白原的含量.

Whole blood, plasma viscosity, and fibrinogen were reduced.

全血粘度，血浆粘度、纤维蛋白原数值降低。

Plasma fibrinogen levels were assayed by tissue thromboplastin.

采用组织凝血活酶法测定血浆纤维蛋白原水平。

Fibrinogen of nothigh cholesterol setis original to ascend occupy 21 %.

非高胆固醇组纤维蛋白原增高者占21%.

Results Fibrinogen of high cholesterol set is original to ascend occupy 80 %.

结果:高胆固醇组纤维蛋白原增高者占80%.

The serum fibrinogen level was decreased significantly in the treatment group.

治疗组血纤维蛋白原水平降低显著,不良反应轻微.

Levels of Plasma Fibrinogen, Serum Bilirubin, Uric Acid and Mild Stenosis of.

纤维蛋白原； 胆红素； 尿酸； 冠状动脉轻度狭窄。

It is suggested that fibrinogen in plasma takes an important role in the the pathogenesis of CHD.

血浆纤维蛋白原在冠心病的发病中可能起重要作用。

The clinical symptoms, hemodynamic indexes and fibrinogen(Fg) contents in blood were observed.

观察两组临床症状、血液流变学指标及纤维蛋白原的变化。

Objective:To assess the relationship between serum concentration of fibrinogen and coronary artery disease.

目的：探讨血浆纤维蛋白原浓度对冠心病发生的预测价值。